CMPS_OUT_1 [2025-04-14 09:32:09 -0400] 3879 Bytes | 994 tokens | Cum: 994 tkns (12.43% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and COMPASS Pathways (CMPS) hit my radar screen, up to 2.9300 from a prev close of 2.8500 Do you think its got more juice or is it lacking potential? It's 9:32:08 AM on Mon Apr 14, 2025 -0400 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: COMPASS Pathways (CMPS)
IPO: 2020-09-18 (4 Years Ago)
Market Cap: $264,118,426
Shares Outstanding: 92,670,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Here’s the first list of news for COMPASS Pathways:

C1 - Mar-28-25 05:01PM - This Is a Test From GlobeNewswire
C2 - Mar-26-25 06:30AM - Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
C3 - Mar-22-25 10:30AM - Psychedelic: Exclusive talk with biotech company Clearmind Medicine
C4 - Mar-21-25 11:50AM - Psychedelic: atai Life Sciences, NRx report quarterly results
C5 - Mar-20-25 11:15AM - Lazard International Strategic Equity Portfolio Q4 2024 Commentary
C6 - Mar-20-25 11:15AM 05:35AM - Lazard International Equity Select Portfolio Q4 2024 Commentary
C7 - Mar-18-25 06:30AM - Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
C8 - Mar-11-25 06:30AM - Compass Pathways to Participate in Stifel Virtual CNS Forum

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: COMPASS Pathways (CMPS).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

CMPS_OUT_3 [2025-04-14 09:32:13 -0400] 578 Bytes | 171 tokens | Cum: 1167 tkns (14.59% of 8k)
==========================================================================

Showing C2 (chunk 1 of 1): C2:
**Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression**
Date: Mar-26-25 06:30AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250326830443/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250326830443/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPS_OUT_5 [2025-04-14 09:32:15 -0400] 968 Bytes | 284 tokens | Cum: 1484 tkns (18.55% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T08:18:34Z - COMPASS Pathways plc (NASDAQ:CMPS) Given Average Rating of "Buy" by Brokerages...
A2 - 2025-03-29T14:16:18Z - COMPASS Pathways' (CMPS) "Overweight" Rating Reaffirmed at Cantor Fitzgerald...
A3 - 2025-03-28T10:32:12Z - BIT Capital GmbH Purchases New Shares in COMPASS Pathways plc (NASDAQ:CMPS)...
A4 - 2025-03-26T08:30:00Z - Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psiloc...
A5 - 2025-03-26T10:36:00Z - Compass Pathways plc: Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 T...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CMPS_OUT_7 [2025-04-14 09:32:16 -0400] 1098 Bytes | 298 tokens | Cum: 1784 tkns (22.30% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**COMPASS Pathways plc (NASDAQ:CMPS) Given Average Rating of "Buy" by Brokerages**Date: 2025-03-31Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/compass-pathways-plc-nasdaqcmps-given-average-rating-of-buy-by-brokerages-2025-03-30/Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have been given an average recommendation of "Buy" by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.83.

CMPS has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research note on Friday. Canaccord Genuity G

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPS_OUT_9 [2025-04-14 09:32:17 -0400] 888 Bytes | 267 tokens | Cum: 2053 tkns (25.66% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-25T18:00:00Z - Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight
B2 - 2024-08-28T10:00:00Z - Compass Pathways to participate in three investor conferences in September
B3 - 2024-08-06T19:13:00Z - 4 Psychedelic Stocks to Consider as Clinical Trials Heat up
B4 - 2024-07-23T08:38:49Z - Compass Pathways initiated at 'Outperform' by RBC, cites $2.3B revenue potential - Investing.com
B5 - 2024-06-26T10:30:00Z - Compass Pathways appoints Lori Englebert as Chief Commercial Officer
B6 - 2024-06-12T10:25:00Z - Should You Buy the Dip on Compass Pathways Stock?

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CMPS_OUT_11 [2025-04-14 09:32:20 -0400] 838 Bytes | 201 tokens | Cum: 2256 tkns (28.20% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/25/3032330/0/en/Comprehensive-Market-Analysis-of-Latest-Published-Different-Types-of-Depression-Reports-DelveInsight.htmlThe depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPS_OUT_13 [2025-04-14 09:32:21 -0400] 1089 Bytes | 285 tokens | Cum: 2642 tkns (33.02% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S5 - 2025-02-27 8-K Item 2.02 Results of Operation and Fin Cond

On February 27, 2025, COMPASS Pathways plc (the Company) issued a press release announcing the Company's financial results for the fourth quarter and year ended December 31, 2024. A copy of this press release is furnished h...

S6 - 2025-02-27 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the CONS financial statements and the related not...

S8 - 2025-01-10 8-K Item1.01 Entry into a Material Definitive Agrmt.

On January 10, 2025, COMPASS Pathways plc (the Company) entered into an underwriting agreement (the Underwriting Agrmt) with TD Securities (USA) LLC (TD Cowen), Cantor Fitzgerald Co., Stifel, Nicolaus Company, Incorporate...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CMPS_OUT_15 [2025-04-14 09:32:24 -0400] 965 Bytes | 248 tokens | Cum: 2892 tkns (36.15% of 8k)
==========================================================================

Showing S5 (chunk 1 of 1): S5:
Item 2.02 Results of Operation and Financial Condition

On February 27, 2025, COMPASS Pathways plc (the Company) issued a press release announcing the Company's financial results for the fourth quarter and year ended December 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CMPS_OUT_17 [2025-04-14 09:32:32 -0400] 6499 Bytes | 1780 tokens | Cum: 4727 tkns (59.09% of 8k)
==========================================================================

This is our set of metrics for {co_name}.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 0 | Perf Month: -18.34% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.13M | Perf Quarter: -19.26% | Short Float: 8.15% | ROE: -81.56% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 4.63 | ROI: -86.36% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 42.31 | Market Cap: 195.37M | Short Interest: 5.23M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.26 | Shs Outstand: 68.55M | Beta: 2.28 | EPS Surprise: -0.57% |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: -3.45% | Shs Float: 64.17M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -21.69% | Inst Own: 36.11% | Sales past 5Y: 0.00% | Earnings: Feb 27 BMO |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: -45.69% | Insider Own: 6.39% | Employees: 166 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 5.17% | Insider Trans: 0.00% | Debt/Eq: 0.21 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by {co_name} officers or majority shareholders (if available).

Inside Trans: COMPASS Pathways plc (CMPS) by Nath Kabir (Chief Executive Officer) on 2025-03-11
- Ordinary Shares: 92000 shares at $0 (D)
- Share Option (Right to Buy): 275000 shares at $0 (D)

Inside Trans: COMPASS Pathways plc (CMPS) by Loxam Teri (Chief Financial Officer) on 2025-03-11
- Ordinary Shares: 25000 shares at $0 (D)
- Share Option (Right to Buy): 76000 shares at $0 (D)

Inside Trans: COMPASS Pathways plc (CMPS) by Goodwin Guy (Chief Medical Officer) on 2025-03-11
- Share Option (Right to Buy): 32000 shares at $0 (D)
- Share Option (Right to Buy): 63000 shares at $0 (D)

Inside Trans: COMPASS Pathways plc (CMPS) by Loxam Teri (Chief Financial Officer) on 2025-03-03
- Ordinary Shares: 4468 shares at $3.67 (D)

Inside Trans: COMPASS Pathways plc (CMPS) by Nath Kabir (Chief Executive Officer) on 2025-02-03
- Ordinary Shares: 15516 shares at $4.31 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -155122000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.95
Average Volume: 1039178.0
30-Day High: 3.46
30-Day Low: 2.66

[Detailed Financials: TTM 2024]
- Total Assets: $213,666,000.0
- Total Liabilities: $58,971,000.0
- Total Equity: $154,695,000.0
- Current Assets: $201,291,000.0
- Current Liabilities: $34,016,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-194,000

[Detailed Financials: FY 2024]
- Total Assets: $213,666,000.0
- Total Liabilities: $58,971,000.0
- Total Equity: $154,695,000.0
- Current Assets: $201,291,000.0
- Current Liabilities: $34,016,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.3

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-194,000
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of COMPASS Pathways (CMPS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about COMPASS Pathways.

2) MARKET_SCORE[]
This conversation was initiated because CMPS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CMPS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CMPS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CMPS to increase 50% from its current price of $2.93, say: PRICE_TARGET[4.4]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of COMPASS Pathways.

11) ETHICAL_RATING[]
Rate COMPASS Pathways’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CMPS_IN_19 [2025-04-14 09:32:32 -0400] 126 Bytes | 29 tokens | Cum: 4968 tkns (62.10% of 8k)
==========================================================================

====================================
[2025-04-14 09:32:32] # Analysis Completed
Elapsed Time: 24.48 seconds